Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall

Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range

Endologix Appoints Jeffrey S. Brown as Chief Operations Officer

Endologix Reports Positive 1-Year Results from the Ovation® LUCY Study

Endologix Appoints Jeffry Fecho as Chief Quality Officer